Drug Profile

Tretinoin microencapsulated - TherapyX

Alternative Names: All-trans retinoic acid - microencapsulated; ATRAXiM

Latest Information Update: 28 Nov 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator TherapyX
Class Antiacnes; Antineoplastics; Cyclohexenes; Keratolytics; Retinoids; Small molecules
Mechanism of Action Protein synthesis inhibitors; Retinoic acid receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Fibrosis

Most Recent Events

28 Nov 2022 No recent reports of development identified for preclinical development in Fibrosis in USA
26 Oct 2018 TherapyX has patents pending for EXStaM technology (TherapyX website, October 2018)
26 Oct 2018 Preclinical trials in Fibrosis in USA (unspecified route) (TherapyX pipeline, October 2018)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com